Abstracts tagged "Oncology"

Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 1986 • ACR Convergence 2024
Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
Juan Sevillano¹, Yixuan Zhou², Juan Ruiz³, Noha Abdel-Wahab⁴ and Maria Suarez-Almazor¹, ¹MD Anderson Cancer Center, Houston, TX, ²Baylor College of Medicine, Houston, ³MD Anderson, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…
Abstract Number: 0474 • ACR Convergence 2024
Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis
Joshua Hsieh¹, Avneet Kaur², Hemant Khandelia³, Teresa Jewell⁴, Aman Singh⁵, Lauren Barkley⁶, Ishan Bansal⁷, Simmi Oberoi⁸ and Namrata Singh⁹, ¹Lakeside High School, Seattle, WA, ²SUNY Upstate, Buffalo, NY, ³AIIMS, New Delhi, Delhi, India, ⁴University of Washington, Seattle, WA, ⁵Rajindra Hospital, Patiala, Punjab, India, ⁶Brandeis University, Boston, MA, ⁷Yale University, New Haven, CT, ⁸Rajindra Hospital, New Delhi, India, ⁹University of Washington, Bellevue, WA
Background/Purpose: Increasing evidence suggests that inflammation, a hallmark of rheumatoid arthritis (RA), is associated with an elevated risk of cancer and can influence cancer outcomes.…
Abstract Number: 2004 • ACR Convergence 2024
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Jose Alfredo Gomez-Puerta¹, Ana Monegal¹, Andrés Ponce², Pilar Peris³, Nuria Martínez⁴, Valentin Ortiz-Maldonado⁴, Ana Triguero⁴, Carlos Fernández de larrea⁴, Julio Delgado⁴, Raimon Sanmartí Sala¹ and Manuel Juan⁵, ¹Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
Abstract Number: 0486 • ACR Convergence 2024
Associations Between Frailty and Incident Cancer and Cancer-related Mortality in Veterans with Rheumatoid Arthritis
Bhavik Bansal¹, Aaron Baraff², Katherine Wysham³, James Andrews⁴, Bryant England⁵, Ted Mikuls⁵, Joshua Baker⁶, Kaleb Michaud⁵, Alexa Meara⁷, Una Makris⁸, Carolyn Presley⁹, ariela orkaby¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁸UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁹The Ohio State Medical Center, Columbus, OH, ¹⁰New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cancer compared to the general population. Aging is one of the most important risk…
Abstract Number: 2117 • ACR Convergence 2024
The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260
Camille Ghio, Robinson Gravier-Dumonceau, Pierre Lafforgue, Roch Giorgi and Thao Pham, Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: Although antiresorptive treatments, including bisphosphonates and denosumab, have demonstrated their efficacy in treating osteoporosis. However, osteonecrosis of the jaw has been reported as a…
Abstract Number: 0916 • ACR Convergence 2024
Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
Mahmut Kaymakci¹, Anuya Natu², Clifford Csizmar², Terra Lasho², Christy Finke², Abhishek Mangaonkar¹, Aref Al-Kali¹, Hassan Alkhateeb¹, Jenna Fernandez², Matthew Koster¹, Cornelia Weyand², Mrinal Patnaik¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
Abstract Number: 2287 • ACR Convergence 2024
Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study
Christine Xue¹, Monica Guma² and Katherine Nguyen², ¹UC San Diego, San Diego, CA, ²UC San Diego, San Diego
Background/Purpose: Sjogren's disease is an autoimmune disorder characterized by chronic lymphocytic inflammation of the salivary and lacrimal glands. Affected individuals are at heightened risk of…
Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Mark Gibson¹, Benjamin Zuckerman², Maryam Adas¹, Mark Russell³, Katie Bechman¹ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
Abstract Number: 1155 • ACR Convergence 2024
Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
Abstract Number: 1158 • ACR Convergence 2024
Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
Sehreen Mumtaz¹, Megan Sullivan², Maximiliano Diaz Menindez³, Emily Craver⁴ and Florentina Berianu⁵, ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵mayo clinic, Ponte Vedra Beach, FL
Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
Abstract Number: 1327 • ACR Convergence 2024
Association of Rheumatoid Arthritis and Frailty Status with Mortality in Patients with Renal Cell Carcinoma
Sherwin Novin¹, Sarah Holt², Maya Swaminathan³, Jonathan Wright², John Gore², Kimme Hyrich⁴, Sizheng Zhao⁵, Jeffrey Sparks⁶, Una Makris⁷, Maria Suarez-Almazor⁸, Petros Grivas², Sarah Psutka² and Namrata Singh⁹, ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³MultiCare, Newcastle, WA, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁵Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁸MD Anderson Cancer Center, Houston, TX, ⁹University of Washington, Bellevue, WA
Background/Purpose: Few studies have evaluated clinical outcomes and prognosis of patients with cancer with and without rheumatoid arthritis (RA). Renal cell carcinoma (RCC) is particularly…
Abstract Number: 1353 • ACR Convergence 2024
Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis
Bhavik Bansal¹, Laura Gold², Katherine Wysham³, James Andrews⁴, Alexa Meara⁵, Carolyn Presley⁶, Elad Sharon⁷, Jiha Lee⁸, Jennifer Barton⁹, Una Makris¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²University of Washington, Seattle, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁶The Ohio State Medical Center, Columbus, OH, ⁷Dana Farber Cancer Institute, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹VA Portland Health Care System/OHSU, Portland, OR, ¹⁰UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
Abstract Number: 1374 • ACR Convergence 2024
Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer
Roba Ghossan¹, Elodie Portier², OLIVIER FOGEL³, Sophie Hecquet¹, Astrid Dauchez¹, Omar AL TABAA⁴, Marion THOMAS⁵, Julia Herrou¹, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹COCHIN HOSPITAL, PARIS, France, ²Cochin Hospital, Bry sur Marne, France, ³AP-HP, Paris, France, ⁴APHP - Cochin Hospital, Paris, France, ⁵APHP, Paris, France, ⁶Université Paris Cité, Paris, France, ⁷Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Managing inflammatory arthritis patients on biologics with a history of cancer remains a complex task in daily rheumatology practice and requires a thoughtful, individualized…
Abstract Number: 1400 • ACR Convergence 2024
Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
Varun Nandakumar¹, Aaron Baraff², Alexander Peterson², Nicholas Smith³, Jennifer Barton⁴, Ann O'Hare², Christopher Li⁵, Noel Weiss³ and Namrata Singh⁶, ¹AIIMS, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³University of Washington, Seattle, WA, ⁴VA Portland Health Care System/OHSU, Portland, OR, ⁵University of Washington, Seattle, ⁶University of Washington, Bellevue, WA
Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].